Thaci D, et al. - Researchers examined the long-term effectiveness and safety of adalimumab (ADA) in kids with severe plaque psoriasis. They observed that 108 cases entered the long-term extension (LTE) out of 114 subjects randomized in the Initial Treatment (IT) period. ADA 0·8mg/kg was given to 93 individuals. They noted a reduction in disease and maintained or further improved after 52 weeks of long-term adalimumab treatment in children (≥4-<18 years) with severe plaque psoriasis. They did not identify new risk factors too.